May 26, 2017
Baar, May 26, 2017 – Quarton International announces that the Belgian Damier Group has acquired Bärbel Drexel GmbH from the private equity firm Finatem. In Germany, Bärbel Drexel is one of the leading suppliers of natural food supplements and natural cosmetics. The company has a well-established brand aimed at a 45+ target group, develops and produces in-house, and sells directly through catalogs, e-commerce, and teleshopping. Through the acquisition of Bärbel Drexel GmbH, Damier strengthens its profile in the field of consumer health care in the German market.
Quarton International was mandated as an exclusive adviser to the company and the majority shareholders. The business deal raises considerable synergy potential for both partners. In the Consumer Healthcare segment, Damier’s current holdings include, among others, the French OTC pharmaceutical company Alpha TopCo and the e-commerce food supplements provider Flinndal. Through the acquisition of Bärbel Drexel GmbH, Damier is expanding its reach in the German market, broadening the product portfolio, and gaining new sales channels. Bärbel Drexel finds a new home in the Damier Group with strong e-commerce competence and expansion possibilities in the neighboring European markets.
“Quarton has elaborated well the strengths of the company, worked out an excellent documentation and their management of the partially difficult sales process was highly competent”, says Irmgard Schade, responsible partner at Finatem.
Bärbel Drexel GmbH is a leading provider of natural food supplements and natural cosmetics in Germany. The company provides for a diversified customer base through the channels of e-commerce, teleshopping, and catalog mail order business. Bärbel Drexel GmbH was founded in Baar (Swabia) in 1996 by the alternative practitioner Bärbel Drexel and her husband using her own naturopathic competence. In 2003, the financial investor Finatem took over the majority of the shares from the founding members.
Damier Group is the Belgian industrial holding company of Yvan Vindevogel, the founder of Vemedia Pharma and Omega Pharma. The Group’s investments are focused on European companies with established brands or innovative technological solutions in the areas of consumer health care and leisure. The subsidiaries are active in Belgium, France, the Netherlands, and Germany. Companies acquired by the Group are integrated into the extensive network of existing holdings, in order to realize synergies.